Pipeline
Indication | Targeted Subgroup | Rationale | |
|---|---|---|---|
© Dale Biotech LLC 2024. All rights reserved. | |||
Non-alcoholic Steatohepatitis
(NASH)
| Obese NASH patients with T2D | Normalizes hepatic central nuclear factor HNF4α, which in multiple models, prevents liver failure;
Prevents increase in fibrosis in multiple NASH models.
| |
Type 2 diabetes
(T2M)
| T2M requiring insulin | In an animal model, eliminates fatty tissue inflammation after only 7 days of oral treatment | |
Peripheral artery disease
(PAD)
| Claudication – Impaired walking distance due to increasing leg pain due to impaired blood flow. | Improves multiple factors of endothelial dysfunction associated with claudication. | |
Critical limb ischemia with diabetic foot infection | Expected to reduce need for amputation by rapidly improving factors associated with disease progression. Proven wound healing properties in wound model. Improves multiple drivers of endothelial dysfunction. Rapidly improves glycemic control. | ||
Coronary artery disease (CAD) | Stable CAD | Prevent progression to heart attacks and complications of atherosclerosis, by improving multiple upstream drivers of disease. | |
COVID-19 | Reduces risk of severe disease | Myocarditis post COVID-19 vaccination | |
Myocarditis post COVID-19 vaccination | Model of myocarditis post-vaccination shows influx of macrophages into heart. DBI-500 can transiently impede macrophage function with adverse effects on hematology. | ||
Long COVID | In NASH and T2D and obesity, the parameters associated with long COVID are reduced. | ||